On the stock market since 2014, it operates in the world of health and science. It has 225 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 59% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $89.0M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 2,849% — still a thick cushion, though costs have been eating into it lately.
There is $89.0M in the vault; even if every debt were paid off, $89.0M would remain.
Over the last 12 months, company executives reported 15 buys and 9 sells. Management buying with its own money is usually read as a good sign.
Over the last 3 years, sales fell about 64% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, FGEN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FGEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.